2015-2019 Future Horizons and Growth Strategies in the World Orthopedics Market: Strategic Assessments of Leading Suppliers - M&A, Technological Capabilities, Marketing Tactics, Joint Ventures, Strategic Directions

Name: 2015-2019 Future Horizons and Growth Strategies in the World Orthopedics Market: Strategic Assessments of Leading Suppliers - M&A, Technological Capab
Brand: Venture Planning Group
SKU: TFC819E45DDEN
Price: 10000 USD
Availability: InStock

September 2015 | 620 pages | ID: TFC819E45DDEN
Venture Planning Group

US$ 10,000.00 ~~US$ 12,500.00~~ -20 %

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer

Checkout Later

Need Help? Ask a Question

Complete report $12,500. Individual company assessments $1,900.

A strategic assessment of the competitive environment is unquestionably one of the highest priority management responsibilities, the task crucial to business survival, growth and profitability. Timely and factual competitive intelligence is vital to the success of all business functions, especially Planning, Marketing, R&D and Manufacturing.

In a highly dynamic and fragmented orthopedics market, besieged by intense competition, rapid pace of technological innovations and the uncertainty regarding future government regulations, the ability to anticipate new competitive product introductions and marketing strategies is particularly important. and can spell the difference between success and failure.

The report is designed to provide the orthopedics industry executives with strategically significant competitor information, analysis and insight, critical to the development and implementation of effective marketing and R&D programs. The study's major objectives include:

To establish a comprehensive, factual and cost-effective information base on performance, capabilities, goals and strategies of the world's leading orthopedics companies.
To help current suppliers realistically assess their financial, marketing and technological capabilities vis-a-vis leading competitors.
To assist potential market entrants in evaluating prospective acquisitions and joint venture candidates.
To complement organizations' internal competitor information gathering efforts by providing strategic analysis, data interpretation and insight.
To identify market niches with significant growth potential.

The companies analyzed in the report include:

Aesculap
Biomet
ConMed
J&J
Medtronic
Smith & Nephew
Stryker
Synthes
Wright Medical Group
Zimmer

Contains 620 pages and 55 tables

INTRODUCTION
WORLDWIDE MARKET AND TECHNOLOGY OVERVIEW
A. Major Routine Chemistry Tests
  1. ALBUMIN
  2. ALKALINE PHOSPHATASE
  3. ALT/SGPT
  4. AMMONIA
  5. AMYLASE
  6. AST/SGOT
  7. BILIRUBIN, TOTAL
  8. BLOOD GASES
  9. BLOOD UREA NITROGEN (BUN)
  10. CALCIUM
  11. CARDIO CRP
  12. CHOLESTEROL
  13. CHOLINESTERASE
  14. CRP
  15. CREATININE
  16. ELECTROLYTES
    a. Carbon Dioxide/Bicarbonate
    b. Chloride
    c. Potassium
    d. Sodium
  17. FERRITIN
  18. FRUCTOSAMINE
  19. GAMMAGLUTAMYL TRANSPEPTIDASE (GGT)
  20. GLUCOSE
  21. HIGH DENSITY LIPOPROTEIN (HDL)
  22. HOMOCYSTEINE
  23. IRON
  24. LACTATE DEHYDROGENASE (LDH)
  25. MAGNESIUM
  26. PHOSPHORUS
  27. PROTEIN
  28. TRIGLYCERIDES
  29. URIC ACID
  30. TROPONIN
B. Therapeutic Drug Monitoring (TDM)
  1. OVERVIEW
  2. CARBAMAZEPINE
  3. CYCLOSPORIN
  4. DIGOXIN
  5. EVEROLIMUS
  6. GENTAMICIN
  7. LAMOTRIGINE/LAMICTAL
  8. LEVETIRACETAM
  9. LIDOCAINE
  10. LITHIUM
  11. NAPA/PROCAINAMIDE
  12. PHENYTOIN
  13. QUINIDINE
  14. SIROLIMUS
  15. TACROLIMUS
  16. THEOPHYLLINE
  17. TOPIRIMATE
  18. VALPROIC ACID
C. Endocrine Function Tests
  1. CORTISOL
  2. ESTRADIOL
  3. FOLLICLESTIMULATING HORMONE (FSH)
  4. GASTRIN
  5. GROWTH HORMONE/IGF-
  6. HUMAN CHORIONIC GONADOTROPIN (HCG)
  7. LH
  8. PROGESTERONE
  9. PTH/IO PTH
  10. PROLACTIN
  11. T3
  12. T3 FREE
  13. T3 UPTAKE
  14. T4 (THYROXINE)
  15. T4 FREE
  16. TBG
  17. TESTOSTERONE
  18. THYROGLOBULIN AB
  19. TPO AB
  20. TSH
D. Tumor Markers And Special Chemistry Tests
  1. AFP
  2. CA 15-
  3. CA 19-9
  4. CA 27-
  5. CARCINOEMBRIONIC ANTIGEN (CEA)
  6. FOLATE/FOLIC ACID
  7. HCG
  8. 25HYDROXY VITAMIN D2 AND D3
  9. OCCULT BLOOD
  10. PROSTATESPECIFIC ANTIGEN (PSA)
  11. THYROGLOBULIN
  12. VITAMIN B-
E. Immunoprotein Tests
  1. COMPLEMENT
    a. C3
    b. C4
  2. FREE LIGHT CHAINS
  3. IMMUNOFIXATION
  4. IMMUNOGLOBULINS (IGA, IGE, IGG, IGM)
  5. HAPTOGLOBIN
  6. PREALBUMIN
  7. PROTEIN ELECTROPHORESIS
F. Drugs of Abuse
  1. OVERVIEW
  2. TEST METHODOLOGIES
  3. AMPHETAMINES
  4. BARBITURATES
  5. BENZODIAZEPINES
  6. CANNABINOIDS/MARIJUANA
  7. COCAINE
  8. LYSERGIC ACID DIETHYLAMIDE (LSD)
  9. METHADONE
  10. METHAQUALONE
  11. OPIATES
  12. PHENCYCLIDINE
  13. TRICYCLIC ANTIDEPRESSANTS
G. INSTRUMENTATION REVIEW: Operating Characteristics and Features of High, Medium, and LowVolume/POC Analyzers Manufactured By:
Abaxis
Abbott
Alere/Inverness
Alfa Wassermann
AMS
Awareness Technologies
Beckman Coulter/Olympus
Binding Site
bioMerieux
Carolina Chemistries
DiaSorin
Grifols
Horiba
Medica
Nova Biomedical
OrthoClinical Diagnostics
Polymedco
Randox
Roche
Siemens
Tosoh
Vital Diagnostics
H. Major In Vitro Diagnostic Technologies And Their Potential Applications
  1. MONOCLONAL AND POLYCLONAL ANTIBODIES
  2. IMMUNOASSAYS
    a. Technological Principle
    d. Chemiluminescence
    c. Enzyme Immunoassays (EIA)
      Overview
      ELISA
      EMIT
      Electrochemical
    d. Radioimmunoassays (RIA)
    e. Immunoprecipitation
    f. Affinity Chromatography
  3. TANDEM MASS SPEC
  4. IT AND AUTOMATION
  5. DRY CHEMISTRY
  6. BIOSENSORS

U.S.A.

A. Executive Summary
B. Business Environment
  1. HEALTH CARE EXPENDITURES
  2. COST CONSCIOUSNESS
  3. INDUSTRY CONSOLIDATION
  4. MANAGED CARE
  5. HOSPITALS
  6. ADMISSIONS
  7. LENGTH OF STAY
  8. INDUSTRY DIVERSIFICATION
  9. PHYSICIAN DEMOGRAPHICS
  10. POPULATION AGING
    a. Chronic Illness
    b. Disease Incidence
    c. Susceptibility to Iatrogenesis
    d. Multiple Illness Cases
  11. LABORATORY REGULATIONS
C. Market Structure
  1. CENTRALIZED TESTING
    a. Hospitals
    b. Commercial/Private Laboratories
  2. DECENTRALIZED TESTING
    a. Physician Offices/Group Practices
    b. PointofCare Testing
    c. Home/Self Testing
    d. Other Decentralized Testing Locations
D. Market Size, Growth and Major Suppliers'
Instrument and Reagent Sales and Market Shares

MAJOR PRODUCT DEVELOPMENT OPPORTUNITIES

DESIGN CRITERIA FOR DECENTRALIZED TESTING PRODUCTS

ALTERNATIVE MARKET PENETRATION STRATEGIES

A. Internal Development
B. Collaborative Arrangements
C. University Contracts
D. Distribution Strategies for Decentralized Testing Markets
  1. MARKETING APPROACHES
  2. PRODUCT COMPLEXITY
  3. CUSTOMER PREFERENCE
  4. ESTABLISHED SUPPLIERS
  5. EMERGING SUPPLIERS
  6. MAJOR TYPES OF DISTRIBUTORS
  7. MARKET SEGMENTATION

POTENTIAL MARKET ENTRY BARRIERS AND RISKS

A. Market Maturity
B. Cost Containment
C. Competition
D. Technological Edge and Limitations
E. Patent Protection
F. Regulatory Constraints
G. Decentralized Testing Market Challenges

COMPETITIVE ASSESSMENTS

Abbott Laboratories
AdnaGen/Alere
Agilent Technologies
Bayer Healthcare
Beckman Coulter/Danaher
Biomedical Diagnostics
BioMerieux
BioRad
DiaSorin
Eiken
Fujirebio
Grifols
Instrumentation Laboratory
Kyowa Medex
Matritech/Alere
OrthoClinical Diagnostics
Quest Diagnostics
Roche
Siemens
Sysmex
Thermo Fisher
Tosoh
Wako
Wallac/PE

LIST OF TABLES

Major Companies Developing or Marketing Albumin Tests
Major Companies Developing or Marketing Alkaline Phosphatase Tests
Major Companies Developing or Marketing ALT/SGPT Tests
Major Companies Developing or Marketing Amylase Tests
Major Companies Developing or Marketing AST/SGOT Tests
Major Companies Developing or Marketing Bilirubin Tests
Major Companies Developing or Marketing Blood Gas Analyzers
Major Companies Developing or Marketing BUN Tests
Major Companies Developing or Marketing Calcium Tests
Major Companies Developing or Marketing Cholesterol Tests
Major Companies Developing or Marketing Creatinine Tests
Major Companies Developing or Marketing Electrolyte Tests
Major Companies Developing or Marketing GGT Tests
Major Companies Developing or Marketing Glucose Tests
Major Companies Developing or Marketing HDL Tests
Major Companies Developing or Marketing Iron Tests
Major Companies Developing or Marketing LDH Tests
Major Companies Developing or Marketing Magnesium Tests
Major Companies Developing or Marketing Phosphorus Tests
Major Companies Developing or Marketing Protein Tests
Major Companies Developing or Marketing Triglycerides Tests
Major Companies Developing or Marketing Uric Acid Tests
Major Companies Developing or Marketing TDM Tests
Major Companies Developing or Marketing Digoxin Tests
Major Companies Developing or Marketing Lithium Tests
Major Companies Developing or Marketing Phenytoin/Dilantin Tests
Major Companies Developing or Marketing Theophylline Tests
Major Companies Developing or Marketing Valproic Acid Tests
Major Companies Developing or Marketing FSH Tests
Major Companies Developing or Marketing HCG Tests
Major Companies Developing or Marketing LH Tests
Major Companies Developing or Marketing Prolactin Tests
Major Companies Developing or Marketing T3 Tests
Major Companies Developing or Marketing T4 Tests
Major Companies Developing or Marketing TSH Tests
Major Companies Developing or Marketing AFP Tests
Major Companies Developing or Marketing CEA Tests
Major Companies Developing or Marketing Ferritin Tests
Major Companies Developing or Marketing Occult Blood Tests
Major Companies Developing or Marketing Prostatic Acid Phosphatase Tests
Major Companies Developing or Marketing PSA Tests
Major Companies Developing or Marketing Vitamin B12/Folate Tests
Major Companies Developing or Marketing CRP Tests
Major Companies Developing or Marketing Drugs of Abuse Tests
Major Companies Developing or Marketing Biosensors for Immunological Testing
Executive Summary Table: U.S.A., Clinical Chemistry and Immunoassay Test Volume and Diagnostics Sales Forecast By Test Category
U.S.A., Hospital Laboratories Performing Chemistry and Immunoassay Tests By Bed Size
U.S.A., Hospital Laboratories, Profiles, Panels and Individual Tests Forecast
U.S.A., Hospital Laboratories, Routine Chemistry Test Volume Forecast by Assay
U.S.A., Hospital Laboratories, TDM Test Volume Forecast by Assay
U.S.A., Hospital Laboratories, Endocrine Function Test Volume Forecast by Assay
U.S.A., Hospital Laboratories, Drugs of Abuse Test Volume Forecast by Assay
U.S.A., Hospital Laboratories, Tumor Markers and Special Chemistry Test Volume Forecast by Assay
U.S.A., Hospital Laboratories, Immunoprotein Test Volume Forecast by Assay
U.S.A., Hospital Laboratories, Routine Chemistry Reagent Market Forecast by Assay
U.S.A., Hospital Laboratories, Endocrine Function Reagent Market Forecast by Assay
U.S.A., Hospital Laboratories, Tumor Markers and Special Chemistry Reagent Market Forecast by Assay
U.S.A., Hospital Laboratories, Immunoprotein Reagent Market Forecast by Assay
U.S.A., Hospital Laboratories, TDM Reagent Market Forecast by Assay
U.S.A., Hospital Laboratories, Drugs of Abuse Reagent Market Forecast by Assay
U.S.A., Clinical Chemistry and Immunoassay Instrument Market Forecast by Analyzer Type
U.S.A., Major Suppliers of Clinical Chemistry Diagnostics Products, Estimated Sales and Market Shares
U.S.A., Major Suppliers of Immunoassay Diagnostics Products, Estimated Sales And Market Shares

2015-2019 Future Horizons and Growth Strategies in the World Orthopedics Market: Strategic Assessments of Leading Suppliers - M&A, Technological Capabilities, Marketing Tactics, Joint Ventures, Strategic Directions

More Publications

Need Help?

Ask a Question

Market Reports